サポート ブログ The Potential of Monoclonal Antibodies in COVID-19 Treatment and Prevention

The Potential of Monoclonal Antibodies in COVID-19 Treatment and Prevention

Biointron 2024-01-20 Read time: 4 mins
Tocilizumab.jpg
Tocilizumab. Image credit: DOI: 10.1186/s12967-020-02339-3

Monoclonal antibodies (mAbs) are produced by a single B-lymphocyte clone and have high specificity for their target antigen. Since their introduction in 1985, mAbs have been used for various therapeutic and prophylactic purposes, such as the treatment of malignancies, autoimmune diseases, infectious organisms, and drug reversal purposes.  

SARS-CoV-2 is the virus that causes COVID-19, and like other viruses in the betacoronavirus genus, several crucial stages of the SARS-CoV-2 life cycle can be potentially inhibited by mAbs. By binding to antigens found on the surface of SARS-CoV-2, mAbs can neutralize the viral proteins and prevent infection of human cells, reducing the severity and duration of illness.1

Monoclonal Antibodies in COVID-19 Treatment 

Although several mAb therapies were developed and granted emergency use authorizations for COVID-19 treatment, the high frequency of the Omicron variant and emerging resistant subvariants caused them to be revoked by the FDA. These therapies included bamlanivimab, casirivimab, and imdevimab. Now, only Actemra (tocilizumab) may be used to treat severe COVID-19 illness for emergency use, effective since December 21, 2022.2 Actemra indirectly targets SARS-CoV-2 by blocking the interleukin-6 (IL-6) receptor. IL-6 is a pro-inflammatory cytokine and an anti-inflammatory myokine that regulates the immune response, inflammatory reaction and bone metabolism.3

MAbs have been shown to be efficient in reducing viral load and improving clinical outcomes, and they still have major benefits and potential as COVID-19 treatments. A study by Andreano et al. identified 453 neutralizing antibodies through single-cell sorting of 4,277 SARS-CoV-2 spike protein-specific memory B cells. Among these, the most potent antibodies recognized the spike protein receptor-binding domain, and subsequently the S1 domain, spike protein trimer, and S2 subunit. By targeting the viral spike protein, mAbs can prevent viral entry.4

Monoclonal Antibodies in COVID-19 Prevention

For pre-exposure prophylaxis, the FDA had previously authorized Evusheld (tixagevimab co-packaged with cilgavimab). However, on January 26, 2023, the FDA revoked its emergency use in the U.S. due to certain variants no longer being neutralized.2 Evusheld would bind to distinct sites on the SARS-CoV-2 spike protein and were optimized with half-life extension and reduced Fc receptor and complement C1q binding.5

The main challenge for mAbs as a COVID-19 therapeutic or prophylactic is the emerging variants and lowered efficacy. There is also a need for broader-based therapies, since Omicron infections may be less clinically severe than infections with earlier variants.

At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


References:

  1. Brobst B, Borger J. Benefits and Risks of Administering Monoclonal Antibody Therapy for Coronavirus (COVID-19) [Updated 2023 May 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 

  2. Centers for Medicare & Medicaid Services. (2023). COVID-19 Monoclonal Antibodies | CMS. https://www.cms.gov/monoclonal 

  3. Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., & Azuma, J. (2009). Extended report: Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Annals of the Rheumatic Diseases, 68(10), 1580-1584. https://doi.org/10.1136/ard.2008.092866 

  4. Andreano, E., Nicastri, E., Paciello, I., Pileri, P., Manganaro, N., Piccini, G., Manenti, A., Pantano, E., Kabanova, A., Troisi, M., Vacca, F., Cardamone, D., Santi, C. D., Torres, J. L., Ozorowski, G., Benincasa, L., Jang, H., Genova, C. D., Depau, L., . . . Rappuoli, R. (2021). Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell, 184(7), 1821-1835. https://doi.org/10.1016/j.cell.2021.02.035 

  5. AstraZeneca. (2021, December 8). Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html 


Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。